Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegvaliase (BMN 165) in adults with PKU (PRISM-1)
NCT01819727Phase 3Completed
- Sponsor
- BioMarin Pharmaceutical
- Start
- May 2013
- Primary completion
- Nov 2015
- Modality
- PEGylated Peptides, Replacement Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pegvaliase in phenylketonuria (PKU) (2 arms), sponsored by BioMarin Pharmaceutical. Primary endpoint: Safety and Tolerability (Incidence of AEs, Hypersensitivity) at 36 weeks. Started May 2013; status: completed.
02
Drugs
pegvaliase
03
Conditions
phenylketonuria (PKU)
Beyond the preview
Go deeper on NCT01819727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01819727.